Search results for "api"

showing 10 items of 8586 documents

"Table 6" of "Measurement of the nuclear modification factor for inclusive jets in Pb+Pb collisions at $\sqrt{s_\mathrm{NN}}=5.02$ TeV with the ATLAS…

2018

No description provided.

5020.0InclusiveProton-Proton ScatteringP P --> JETS XRapidity DependenceD2SIG/DPT/DYRAPJet ProductionTransverse Momentum DependenceDouble Differential Cross Section
researchProduct

"Table 3" of "Measurement of the nuclear modification factor for inclusive jets in Pb+Pb collisions at $\sqrt{s_\mathrm{NN}}=5.02$ TeV with the ATLAS…

2018

No description provided.

5020.0InclusiveSiGMA(PTRECO / PTTRUTH)P P --> JETS XRapidity DependenceDouble Differential DistributionJet ProductionTransverse Momentum Dependence
researchProduct

"Table 13" of "$\Upsilon$ production and nuclear modification at forward rapidity in Pb-Pb collisions at $\mathbf{\sqrt{\textit{s}_{\textbf{NN}}}=5.0…

2021

Interpolated rapidity-differential cross section for $\Upsilon(1\mathrm{S}) \rightarrow \mu^{+}\mu^{-}$ in proton–proton collisions. Results used for the determination of the nuclear modification factor of $\Upsilon(1\mathrm{S})$ as a function of rapidity (Figure 7).

5020.0Proton-Proton ScatteringP P --> UPSI(1S) < MU+ MU- > XRapidity DependenceNuclear TheoryHigh Energy Physics::ExperimentUpsilonDSIG/DYRAPCross SectionNuclear Experiment
researchProduct

"Table 14" of "$\Upsilon$ production and nuclear modification at forward rapidity in Pb-Pb collisions at $\mathbf{\sqrt{\textit{s}_{\textbf{NN}}}=5.0…

2021

Interpolated rapidity-differential cross section for $\Upsilon(2\mathrm{S}) \rightarrow \mu^{+}\mu^{-}$ in proton–proton collisions. Results used for the determination of the nuclear modification factor of $\Upsilon(2\mathrm{S})$ as a function of rapidity (Figure 7).

5020.0Proton-Proton ScatteringP P --> UPSI(2S) < MU+ MU- > XRapidity DependenceNuclear TheoryHigh Energy Physics::ExperimentUpsilonDSIG/DYRAPCross SectionNuclear Experiment
researchProduct

"Table 9" of "$\Upsilon$ production and nuclear modification at forward rapidity in Pb-Pb collisions at $\mathbf{\sqrt{\textit{s}_{\textbf{NN}}}=5.02…

2021

Nuclear modification factor of $\Upsilon(1\mathrm{S})$ as a function of rapidity for the 0–90% centrality interval.

5020.0Rapidity DependenceUpsilonPb Pb --> UPSI(1S) < MU+ MU- > XLead-Lead ScatteringRAANuclear Modification Factor
researchProduct

"Table 10" of "$\Upsilon$ production and nuclear modification at forward rapidity in Pb-Pb collisions at $\mathbf{\sqrt{\textit{s}_{\textbf{NN}}}=5.0…

2021

Nuclear modification factor of $\Upsilon(2\mathrm{S})$ as a function of rapidity for the 0–90% centrality interval.

5020.0Rapidity DependenceUpsilonPb Pb --> UPSI(2S) < MU+ MU- > XLead-Lead ScatteringRAANuclear Modification Factor
researchProduct

A conspectus of Tephroseris (Asteraceae: Senecioneae) in Europe outside Russia and notes on the decline of the genus

2021

Tephroseris is generally considered a difficult genus. Based on the examination of extensive herbarium material and considering the existing literature, we recognize seven species in Europe outside Russia. These are T. palustris, T. integrifolia with subsp. integrifolia, subsp. aurantiaca, subsp. capitata, subsp. maritima, subsp. serpentini and subsp. “tundricola”, T. balbisiana, T. crispa, T. helenitis, T. longifolia and T. papposa. Phylogenetic analysis of ITS and ETS sequences showed that these species fall into three lineages. These are: (1) T. palustris, clearly related to Arctic species of the genus; (2) T. integrifolia; and (3) the remaining species. Molecular dating of the T. integr…

580CompositaebiologyLineage (evolution)habitat lossWilldenowiaPlant ScienceSenecioneaeAsteraceaeAsteraceaebiology.organism_classificationEuropeHerbariumGeographyTephroserisGenus500 Naturwissenschaften und Mathematik::580 Pflanzen (Botanik)::580 Pflanzen (Botanik)CapitataBotanyglacial relicEcology Evolution Behavior and Systematicsglobal changeETS
researchProduct

Adaptación de la terapia híbrida de activación conductual para la depresión

2017

La depresión es un trastorno mental serio. Según la Organización Mundial de la Salud (WHO), es la principal causa de discapacidad a nivel mundial, padeciéndola más de 300 millones de personas en el mundo. En la región de las Américas, de forma particular, la depresión es considerada un problema de salud grave, con una tasa de prevalencia aproximadamente del 5% por cada 100 mil habitantes. Específicamente, en Chile la tasa de prevalencia de la depresión en mayores de quince años es el equivalente al 5% de la población, siendo el cuarto país de América Latina con mayor prevalencia de esta enfermedad. Por tanto se precisa disponer de estrategias de intervención eficaces, breves y económicament…

610307 PsicoterapiaTratamiento psicológico depresión320105 Psicología ClínicaTerapia Activación Conductual DepresiónPsicología Clínica
researchProduct

Efecto de la radioterapia en glándulas salivales accesorias.

2005

El objetivo de este trabajo es estudiar las alteraciones que las radiacionesionizantes producen sobre las glándulas salivales accesorias labiales. Ennuestro estudio se seleccionaron sujetos diagnosticados de un tumor malignode cabeza y cuello que iban a recibir radioterapia dentro de su tratamiento,incluyendo los labios dentro del campo de irradiación. Se evaluó la secreciónsalival y las alteraciones morfológicas de las glándulas en el momento deldiagnóstico y a los tres meses de finalizar el tratamiento radioterápico.Se incluyeron en el estudio 17 sujetos. Antes de la radioterapia lasecreción salival media fue de 0,21 ml/m; en cuatro de los sujetos existía atrofiaglandular leve antes de di…

616xerostomía.Facultat de Medicina i OdontologiaGlándula salival menorradioterapia
researchProduct

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in C…

2021

Abstract Background: Adoptive cell immunotherapies for opportunistic virus in immunocompromised patients using haploidentical memory T cells have shown to be safe and effective. Since severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state we have proposed that a similar strategy could be proven to be efficient for COVID-19 patients. This is a study protocol of an open-label, multicenter, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of the administration of a single dose of allogenic SARS-CoV-2 specific memory CD45RA - T cells and Natural Killer (NK)…

704.Cellular Immunotherapies: Clinicalbusiness.industryImmunologyCell BiologyHematologymedicine.disease_causemedicine.diseaseBiochemistryPneumoniaPhase i iiMulti center studyImmunologymedicineDose escalationbusinessCoronavirusBlood
researchProduct